CD8A and neoplasm: In the B16F10 tumor-bearing mouse model, MSNM@CY1-4 can significantly inhibit the activity of IDO in blood and tumor tissues, ameliorate the immunosuppressive TME and TDLN, significantly reduce Tregs infiltration, increase CD4+ T cells and CD8+ T cells infiltration, and improve anti-tumor effects.